Antigen-MHC class II complex

The **antigen-MHC class II complex** consists of an exogenous peptide (antigen) presented on the surface of professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells, bound within the peptide-binding groove of a major histocompatibility complex class II (MHC II) molecule. MHC class II molecules are membrane-bound heterodimers formed by an α and β chain, and are specialized for presenting peptides typically 13–25 amino acids in length that are derived from extracellular proteins processed in the endosome/lysosome pathway of the APC[3][4][2]. The complex interacts specifically with the T cell receptor on CD4^+^ T lymphocytes, leading to T cell activation, differentiation, and initiation of immune responses[3][4][6]. Dysregulation of antigen presentation via MHC class II is implicated in autoimmunity, infection, some cancers, and immunotherapy adverse events[3][6]. Context and technical clarifications: - The search term "Antigen presented by major histocompatibility complex class II" is a mechanistic event, not a singular receptor or target—thus, it is **not a typical therapeutic target**. Rather, the MHC class II molecule (and specific allelic variants, such as HLA-DR, HLA-DP, HLA-DQ) is the protein target relevant in immunology and therapy[3][4]. - There is **no standard canonical abbreviation** for the complex; literature typically uses "peptide–MHC class II" or "pMHC class II." - The **complex is not directly targeted by drugs**, but many immunomodulatory drugs (for example, monoclonal antibodies, checkpoint inhibitors) modulate pathways that affect antigen presentation; also, some therapies are designed to exploit or evade this pathway in cancer or autoimmunity. - The **MHC class II family** includes several isoforms (HLA-DR, HLA-DP, HLA-DQ) that differ in their peptide repertoire and disease associations[3]. - **Biomarker context:** Specific HLA class II allele types are used as biomarkers for patient selection or monitoring, especially in autoimmune and infectious diseases, and in cancer immunotherapy for predicting immune-related adverse effects[3]. This entity—antigen-MHC class II complex—is essential for *immune activation* but is not a distinct therapeutic receptor, enzyme, or direct drug target as commonly catalogued in drug discovery databases. It is more accurately described as a *complex or functional entity involved in cell-cell communication within the adaptive immune system*[4][3][2][6].

Other names

Major histocompatibility complex class II–bound peptidepeptide–MHC class II complex